Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
India’s Economic Activity Stays Subdued as Manufacturing Weakens
India’s economic activity remained subdued in August as a slowdown in manufacturing was offset by slight growth in the services sector, a flash survey by HSBC Holdings Plc showed Friday.
Making Tech for the Battlefield Fuels 80% Rally in Swedish Stock
A small Swedish firm is Europe’s best-performing defense stock in 2026, an ascent its chief executive puts down to a “third wave” of military spending that’s focused more on computer systems and…
Takaful Malaysia delivers resilient Q2 FY2026 performance with RM2b takaful revenue and RM305.6m PBZT
KUALA LUMPUR, Aug 22 — Syarikat Takaful Malaysia Keluarga Berhad (Takaful Malaysia or the Group) delivered another...
Nigerian equities sell-off deepens across major sectors, wiping out N5.4 trillion in 8 days
The Nigerian equities market extended its bearish run on Thursday, August 20, 2026, as renewed selling pressure across major sectors wiped out approximately N440.33 billion on Thursday, marking the…
Iranian Oil Supply to Chinese Refiners Squeezed by US Blockade
The amount of Iranian oil that’s readily available to Chinese buyers is rapidly running out, showing the effectiveness of the US blockade of the country’s ports at choking off revenue to Tehran.
CFTC prepares crypto rules as Clarity Act stalls
Commodity Futures Trading Commission Chairman Michael S. Selig has instructed agency staff to prepare a regulatory framework for cryptocurrency markets that could be advanced if Congress fails to…